The analyst explains, “Exelixis reported COMETRIQ sales of $14M in 2Q:16 and CABOMETYX renal cell carcinoma (RCC) sales of $17.6M including $6.5-7M in inventory stocking. These results beat our sales estimate of $10.5 million in COMETRIQ and $7.5 million of CABOMETYX. We now forecast U.S. CABOMETYX sales of $88M in 2016 and $224M in 2017. Exelixis ended 1Q:16 with cash of $384M, retains a $287.5M convertible note due in 2019 and owes Silicon Valley Bank $80M and Deerfield $107M due in July 2018. We remain Neutral, however are increasing our price target to $8 from $5 based on increased CABOMETYX sales.”
According to TipRanks, the analyst is ranked #3,371 of 4,085 analysts. He maintains a success rate of 37%.